AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03664804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Study Drug was Administered in this Study
Description: No study drug was administered in this study
Study NCT04219254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI1206
Description: BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase
Study NCT02819089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
Study NCT01742897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Study NCT02431377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold
Description: A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
Study NCT03188224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyTransition app
Description: MyTransition app is designed to support youth moving from pediatric to adult healthcare.
Study NCT00801567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy (MRS)
Description: 90-minute magnetic resonance scan.
Study NCT03196336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacotherapy follow-up care
Description: The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
Study NCT03749772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
Study NCT00214916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive insulin therapy (Actrapid IV to normoglycemia)
Description: intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
Study NCT00214916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)
Description: conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
Study NCT03775746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75Mg Tablet
Description: Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
Study NCT03775746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75Mg Tablet
Description: Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
Study NCT03775746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5Mg Tablet
Description: Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
Study NCT03775746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90Mg Tablet
Description: Prevention of atherothrombotic events in patients with acute coronary syndrome \[in combination with aspirin\]
Study NCT02566590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
Study NCT02566590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
Study NCT02566590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-protein placebo supplement
Description: supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
Study NCT03878758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Nano™ PRO
Description: Insulin Pen needle
Study NCT03878758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33G Artsana Insupen Extr3me
Description: Insulin Pen Needle
Study NCT03878758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 34G Artsana Insupen Extr3me
Description: Insulin Pen Needle
Study NCT03878758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple Diagnostics Comfort EZ™
Description: Insulin Pen Needle
Study NCT02506023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
Study NCT01728844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: beta-tricalcium phosphate alone
Study NCT01728844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFeBGS 0.1%
Study NCT01831674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride Extended-Release Tablets USP 750
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
Study NCT01831674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended-Release Tablets USP 750
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
Study NCT01831674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE®XR tablet 750 mg
Description: GLUCOPHAGE®XR 750 mg once a day
Study NCT01831674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLUCOPHAGE®XR tablet 750 mg
Description: GLUCOPHAGE®XR 750 mg once a day
Study NCT04802187 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RADx CHCs testing intervention strategy
Description: The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.
Study NCT04802187 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care control
Description: CHCs implement testing strategies in accordance with their usual supports.
Study NCT00317304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
Study NCT00119366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV
Study NCT00119366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00119366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT01728844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFeBGS 0.3%
Study NCT01728844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFeBGS 0.4%
Study NCT03956940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intplex test
Description: Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
Study NCT03438994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Play.Care
Description: iPad based game to assess movement as the player interacts with the screen
Study NCT03438994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Play.Care
Description: iPad based game to assess movement as the player interacts with the screen
Study NCT03886298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency splanchnic denervation
Description: the authors will denervate the splanchnic nerves via radiofrequency
Study NCT03886298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrocrural celiac denervation
Description: the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
Study NCT00233948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate
Description: Given orally
Study NCT00233948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT00233948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00233948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00233948 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT00233948 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study NCT00233948 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT02327975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax.
Study NCT02327975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile group
Description: The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
Study NCT00233948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT01838850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS8635 20/5/12.5mg and placebo
Description: Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day.
Study NCT01838850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmetec® Plus 20/12.5mg and placebo
Description: Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day.
Study NCT00550459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 15-60 mg oral tablet given once a day for 21 days.
Study NCT00550459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given once daily for 21 days
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
Study NCT02327975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No received intervention.
Study NCT03189550 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS perioperative care
Description: Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
Study NCT03189550 — intervention group
Intervention type: PROCEDURE
Intervention: Standard perioperative care
Description: Standard perioperative care prior to implementation of ERAS care pathway
Study NCT03189550 — intervention group
Intervention type: PROCEDURE
Intervention: Noninvasive hemodynamic monitoring
Description: Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
Study NCT02301299 — intervention group
Intervention type: BEHAVIORAL
Intervention: Community-based Stroke Awareness Program
Description: A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
Study NCT01245998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: dalteparin 5000 I.U./24 h s.c. for 6 weeks
Study NCT01245998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: dalteparin 15000 I.U./24 h s.c. for 6 weeks
Study NCT00119366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo PBSC transplantation
Study NCT00119366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation
Study NCT00119366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT00119366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine
Description: All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine
Description: All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone (oral)
Description: All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone (oral)
Description: All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone (depot)
Description: All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone (depot)
Description: All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
Study NCT02543944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study NCT00119366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01193179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262
Description: Oral administration of tablets for 52 weeks
Study NCT02864355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goal Directed Therapy
Description: Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
Study NCT02325076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirodoc
Description: A device to detect the physical condition of the lungs
Study NCT01073085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based automated coaching by e-mails
Study NCT04492111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post-extraction dental implant
Description: Insertion of a dental implant immediately after tooth extraction.
Study NCT01073085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help guide
Study NCT03771287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oticon OpenSound Navigator speech enhancement algorithm
Description: OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
Study NCT04492111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-extraction dental implant
Description: Insertion of a dental implant immediately after tooth extraction.
Study NCT00654979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeFlo IVC Filter
Description: SafeFlo IVC Filter
Study NCT00306059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury
Description: Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
Study NCT02754258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: 60 days on oral methylphenidate administered 2 times daily before lunch and supper.
Study NCT02507635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: administration of Levocetirizine 5 mg/day for 4 weeks
Study NCT02507635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: administration of Desloratadine 5 mg/day for 4 weeks
Study NCT03771287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oticon omni-directional microphone algorithm
Description: Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
Study NCT02088697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02088697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASC-01
Study NCT02688738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study NCT01564303 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
Description: to evaluate the effect of the above agents on Kidney functioning parameters
Study NCT01564303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
Description: to evaluate the effect of the above agents on Kidney functioning parameters